Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC Paclitaxel + Cisplatin in Ovarian Cancer
NCT05620654Phase 1Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in ovarian cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Dose-Limiting Toxicity at 3 weeks. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05620654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620654.